Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up

Objective: Ulcerative colitis usually affects the rectum and potentially can involve the whole colon. Noninvasive methods such as fecal calprotectin measurement may be considered as a reliable and inexpensive approach in assessing disease severity or treatment change strategy. Methods: In this retro...

Full description

Bibliographic Details
Main Authors: Mahsa Mahdipour, Afshin Shafaghi, Fariborz Mansour-Ghanaei, Amineh Hojati, Farahnaz Joukar, Sara Mavaddati
Format: Article
Language:English
Published: Thieme Revinter Publicações Ltda. 2019-04-01
Series:Journal of Coloproctology
Online Access:http://www.sciencedirect.com/science/article/pii/S223793631830532X
id doaj-792fc746cf754b2dae33dd61af7ea796
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Mahsa Mahdipour
Afshin Shafaghi
Fariborz Mansour-Ghanaei
Amineh Hojati
Farahnaz Joukar
Sara Mavaddati
spellingShingle Mahsa Mahdipour
Afshin Shafaghi
Fariborz Mansour-Ghanaei
Amineh Hojati
Farahnaz Joukar
Sara Mavaddati
Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
Journal of Coloproctology
author_facet Mahsa Mahdipour
Afshin Shafaghi
Fariborz Mansour-Ghanaei
Amineh Hojati
Farahnaz Joukar
Sara Mavaddati
author_sort Mahsa Mahdipour
title Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
title_short Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
title_full Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
title_fullStr Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
title_full_unstemmed Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
title_sort fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up
publisher Thieme Revinter Publicações Ltda.
series Journal of Coloproctology
issn 2237-9363
publishDate 2019-04-01
description Objective: Ulcerative colitis usually affects the rectum and potentially can involve the whole colon. Noninvasive methods such as fecal calprotectin measurement may be considered as a reliable and inexpensive approach in assessing disease severity or treatment change strategy. Methods: In this retrospective cross-sectional study, records of 56 ulcerative colitis patients who hospitalized with exacerbation between May 2016 and April 2017 were assessed based on IBD Data Bank Software in Gastrointestinal and Liver Diseases and Research Center (GLDRC), Guilan province, Iran between. A questionnaire of demographic characteristics, clinical findings and fecal calprotectin level was completed. Montreal classification severity of ulcerative colitis and Mayo disease activity index were scored. Data were analyzed for descriptive and analytical analysis. Results: Fecal calprotectin was significantly different in terms of disease severity based on both Mayo score (p = 0.007) and Montreal classification (p = 0.001). In patients with mild symptoms, no increase in fecal calprotectin was observed, but in patients with moderate and severe elevations in fecal calprotectin levels was significant. Also, C-Reactive Protein surge was related to disease severity (p = 0.02). Furthermore, regression comparison among high-chance patients based on fecal calprotectin was significantly related to higher Erythrocyte Sedimentation Rate levels and smoking, p = 0.01 and p = 0.05, respectively. Conclusion: It seems fecal calprotectin levels are related to the disease severity. Non-invasive methods, such as fecal calprotectin assay, may seem to be an alternative to aggressive, costly and time-consuming methods, such as colonoscopy and biopsy, to reduce the suffering of patients and ultimately help improve the patients’ life quality. Resumo: Objetivo: A colite ulcerativa geralmente afeta o reto, podendo acometer todo o cólon. Métodos não invasivos, como a dosagem de calprotectina fecal, podem ser uma abordagem confiável e barata para a avaliação da gravidade da doença ou da estratégia de mudança de tratamento. Métodos: Neste estudo transversal retrospectivo, os registros de 56 pacientes com colite ulcerativa que foram hospitalizados devido a exacerbação entre maio de 2016 e abril de 2017 foram avaliados usando o software IBD Data Bank no Centro de Pesquisa e Doenças Gastrointestinais e Hepáticas (GLDRC), na província de Guilan, Irã. Foi aplicado um questionário de características demográficas, achados clínicos e nível de calprotectina fecal. Foram usados o escore de Mayo de atividade da doença e a classificação de Montreal da gravidade da colite ulcerativa. Os dados foram analisados de forma descritiva e analítica. Resultados: A calprotectina fecal apresentou diferença significativa em termos de gravidade da doença com base no escore de Mayo (p = 0,007) e na classificação de Montreal (p = 0,001). Em pacientes com sintomas leves, nenhum aumento na calprotectina fecal foi observado. Entretanto, em pacientes com sintomas moderados e severos, o aumento nos níveis de calprotectina fecal foi significativo. Além disso, o aumento nos níveis de proteína C reativa foi associado à gravidade da doença (p = 0,02). A análise da regressão entre pacientes considerados de alto risco com base na calprotectina fecal indicou uma associação significativa com níveis elevados da taxa de sedimentação de eritrócitos e tabagismo (p = 0,01 e p = 0,05, respectivamente). Conclusão: Os níveis de calprotectina fecal parecem estar relacionados com a gravidade da doença. Métodos não invasivos, como o estudo de calprotectina fecal, podem ser uma alternativa a métodos agressivos, caros e demorados, tais como colonoscopia e biópsia, reduzindo o sofrimento e ajudando a melhorar a qualidade de vida dos pacientes. Keywords: Calprotectin, Inflammatory bowel disease, Ulcerative colitis, Inflammation, Palavras-chave: Calprotectina, Doença inflamatória intestinal, Colite ulcerativa, Inflamação
url http://www.sciencedirect.com/science/article/pii/S223793631830532X
work_keys_str_mv AT mahsamahdipour fecalcalprotectinroleindiagnosisofulcerativecolitisandtreatmentfollowup
AT afshinshafaghi fecalcalprotectinroleindiagnosisofulcerativecolitisandtreatmentfollowup
AT fariborzmansourghanaei fecalcalprotectinroleindiagnosisofulcerativecolitisandtreatmentfollowup
AT aminehhojati fecalcalprotectinroleindiagnosisofulcerativecolitisandtreatmentfollowup
AT farahnazjoukar fecalcalprotectinroleindiagnosisofulcerativecolitisandtreatmentfollowup
AT saramavaddati fecalcalprotectinroleindiagnosisofulcerativecolitisandtreatmentfollowup
_version_ 1721327936065241088
spelling doaj-792fc746cf754b2dae33dd61af7ea7962021-07-02T14:34:26ZengThieme Revinter Publicações Ltda.Journal of Coloproctology2237-93632019-04-01392115120Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-upMahsa Mahdipour0Afshin Shafaghi1Fariborz Mansour-Ghanaei2Amineh Hojati3Farahnaz Joukar4Sara Mavaddati5Guilan University of Medical Sciences (GUMS), Gastrointestinal and Liver Diseases Research Center (GLDRC), Rasht, IranGuilan University of Medical Sciences (GUMS), GI Cancer Screening and Prevention Research Center (GCSPRC), Rasht, IranGuilan University of Medical Sciences (GUMS), Gastrointestinal and Liver Diseases Research Center (GLDRC), Rasht, Iran; Corresponding author.Guilan University of Medical Sciences (GUMS), Caspian Digestive Diseases Research Center (CDDRC), Rasht, IranGuilan University of Medical Sciences (GUMS), Caspian Digestive Diseases Research Center (CDDRC), Rasht, IranGuilan University of Medical Sciences (GUMS), Gastrointestinal and Liver Diseases Research Center (GLDRC), Rasht, IranObjective: Ulcerative colitis usually affects the rectum and potentially can involve the whole colon. Noninvasive methods such as fecal calprotectin measurement may be considered as a reliable and inexpensive approach in assessing disease severity or treatment change strategy. Methods: In this retrospective cross-sectional study, records of 56 ulcerative colitis patients who hospitalized with exacerbation between May 2016 and April 2017 were assessed based on IBD Data Bank Software in Gastrointestinal and Liver Diseases and Research Center (GLDRC), Guilan province, Iran between. A questionnaire of demographic characteristics, clinical findings and fecal calprotectin level was completed. Montreal classification severity of ulcerative colitis and Mayo disease activity index were scored. Data were analyzed for descriptive and analytical analysis. Results: Fecal calprotectin was significantly different in terms of disease severity based on both Mayo score (p = 0.007) and Montreal classification (p = 0.001). In patients with mild symptoms, no increase in fecal calprotectin was observed, but in patients with moderate and severe elevations in fecal calprotectin levels was significant. Also, C-Reactive Protein surge was related to disease severity (p = 0.02). Furthermore, regression comparison among high-chance patients based on fecal calprotectin was significantly related to higher Erythrocyte Sedimentation Rate levels and smoking, p = 0.01 and p = 0.05, respectively. Conclusion: It seems fecal calprotectin levels are related to the disease severity. Non-invasive methods, such as fecal calprotectin assay, may seem to be an alternative to aggressive, costly and time-consuming methods, such as colonoscopy and biopsy, to reduce the suffering of patients and ultimately help improve the patients’ life quality. Resumo: Objetivo: A colite ulcerativa geralmente afeta o reto, podendo acometer todo o cólon. Métodos não invasivos, como a dosagem de calprotectina fecal, podem ser uma abordagem confiável e barata para a avaliação da gravidade da doença ou da estratégia de mudança de tratamento. Métodos: Neste estudo transversal retrospectivo, os registros de 56 pacientes com colite ulcerativa que foram hospitalizados devido a exacerbação entre maio de 2016 e abril de 2017 foram avaliados usando o software IBD Data Bank no Centro de Pesquisa e Doenças Gastrointestinais e Hepáticas (GLDRC), na província de Guilan, Irã. Foi aplicado um questionário de características demográficas, achados clínicos e nível de calprotectina fecal. Foram usados o escore de Mayo de atividade da doença e a classificação de Montreal da gravidade da colite ulcerativa. Os dados foram analisados de forma descritiva e analítica. Resultados: A calprotectina fecal apresentou diferença significativa em termos de gravidade da doença com base no escore de Mayo (p = 0,007) e na classificação de Montreal (p = 0,001). Em pacientes com sintomas leves, nenhum aumento na calprotectina fecal foi observado. Entretanto, em pacientes com sintomas moderados e severos, o aumento nos níveis de calprotectina fecal foi significativo. Além disso, o aumento nos níveis de proteína C reativa foi associado à gravidade da doença (p = 0,02). A análise da regressão entre pacientes considerados de alto risco com base na calprotectina fecal indicou uma associação significativa com níveis elevados da taxa de sedimentação de eritrócitos e tabagismo (p = 0,01 e p = 0,05, respectivamente). Conclusão: Os níveis de calprotectina fecal parecem estar relacionados com a gravidade da doença. Métodos não invasivos, como o estudo de calprotectina fecal, podem ser uma alternativa a métodos agressivos, caros e demorados, tais como colonoscopia e biópsia, reduzindo o sofrimento e ajudando a melhorar a qualidade de vida dos pacientes. Keywords: Calprotectin, Inflammatory bowel disease, Ulcerative colitis, Inflammation, Palavras-chave: Calprotectina, Doença inflamatória intestinal, Colite ulcerativa, Inflamaçãohttp://www.sciencedirect.com/science/article/pii/S223793631830532X